Skip to main content
Demetrios Vavvas, MD, Ophthalmology, Boston, MA, Massachusetts Eye and Ear

DemetriosVavvasMDPh.D.(He/Him)

Ophthalmology Boston, MA

Retinal Disease

Solman and Libe Friedman Professor of Ophthalmology, Harvard Medical School Co-Director Ocular Regenerative Medical Institute Associate Director Retina Service MEEI Principal Investigator Angiogenesis Laboratory Mass. Eye and Ear Infirmary and Mass General Hospital

Dr. Vavvas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Vavvas' full profile

Already have an account?

Education & Training

  • Massachusetts Eye and Ear Infirmary/Harvard Medical School
    Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolChief Residency, Ophthalmology, 2003 - 2004
  • Massachusetts Eye and Ear Infirmary/Harvard Medical School
    Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 2000 - 2004
  • Boston University Medical Center
    Boston University Medical CenterInternship, Internal Medicine, 1999 - 2000
  • Boston University School of Medicine
    Boston University School of MedicineClass of 1999
  • Massachusetts Eye and Ear Infirmary/Harvard Medical School
    Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolFellowship, Surgical Retina and Vitreous
  • McGill University
    McGill UniversityB.Sc., Biology/ Neuroscience, First Class Honors

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2003 - 2026
  • American Board of Ophthalmology Ophthalmology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Permanent Neuroglial Remodeling of the Retina Following Infiltration of CSF1R Inhibition-Resistant Peripheral Monocytes  
    Claes H Dohlman, James Chodosh, Demetrios G Vavvas, Reza Dana, Proceedings of the National Academy of Sciences

Press Mentions

  • Apellis’ Syfovre Approved as First Treatment for Geographic Atrophy Despite Uncertain Clinical Benefit
    Apellis’ Syfovre Approved as First Treatment for Geographic Atrophy Despite Uncertain Clinical BenefitMarch 7th, 2023
  • Apellis Wins FDA Approval of First Drug for Type of Vision Loss
    Apellis Wins FDA Approval of First Drug for Type of Vision LossFebruary 17th, 2023
  • RETINA CONVERSATIONS: A Conversation with Evangelos S. Gragoudas, MD
    RETINA CONVERSATIONS: A Conversation with Evangelos S. Gragoudas, MDMarch 1st, 2019
  • Join now to see all

Hospital Affiliations